R. Panchanath, Joint Managing Director, CPC Diagnostics Private Limited

Indian market is price sensitive where the end consumer has very little access to financial support from the government or the insurance sector. Our 30 years of experience has given us a very good understanding of the needs of our market.

CPC Diagnostics began its operations 30 years ago as a marketing organization, representing international diagnostic principals in India. The experience we harnessed in providing support and training to our customers became the platform on which we built our foundation for manufacturing.

Our manufacturing commenced in 2005 when we set up a facility for manufacturing IVD instruments. We initially focused on hematology and then expanded into immunology and pre-analytical automation. We are the first in India to design, develop, and indigenously manufacture a 3-part differential hematology analyzer. Another first is our automated tube labeler for phlebotomy. Our aim is to provide unique, innovative, and cost-effective solutions to the Indian diagnostic market.

Subsequently, we extended our manufacturing operations into clinical chemistry reagents. We now manufacture a range of clinical chemistry reagents in different pack sizes. We manufacture system packs for different automated instruments. Usage of system packs makes the tests cost effective, without compromising on reliability and repeatability.

In manufacturing, we design and develop products, keeping the Indian IVD market and markets similar to ours in mind. Most of the IVD instruments available are designed in western countries and are also designed for western laboratory practices. In India, we face challenges in power supply, space constraint in labs, and availability of qualified and skilled technicians. Besides, the Indian market is price sensitive where the end consumer (the patient) has very little access to financial support from the government or the insurance sector. Our 30 years of experience has given us a very good understanding of the needs of our market.

At the same time, we are determined that our discerning customers should have access to products of international standards, manufactured in India. In CPC, at every stage of manufacturing, we have a series of checks and balances to make sure that we do not compromise on quality at the altar of cost.

This is the key factor which enabled us to win the Times of India Medical Innovation Award in 2014. We are also proud that we are adding our contribution to the Make in India program through the indigenization of some of the IVD products that our country needs. With continued focus and determination, we are confident of more indigenization and innovation in the coming years.


 

randox

Digital version